156 related articles for article (PubMed ID: 6825130)
1. Inefficacy of sc Corynebacterium parvum in stage I malignant melanoma: preliminary results of a single-institution pilot study.
Murray JL; Ishmael DR; Bottomley RH; Grozea PN; Lee ET
Cancer Treat Rep; 1983 Feb; 67(2):191-2. PubMed ID: 6825130
[No Abstract] [Full Text] [Related]
2. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma.
Karakousis CP; Didolkar MS; Han T
Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032
[No Abstract] [Full Text] [Related]
3. Malignant angioendothelioma--effect of immunotherapy with Corynebacterium parvum.
Tan SG; Cotterill JA; Roberts MM; Cunliffe WJ
Acta Derm Venereol; 1978; 58(6):551-3. PubMed ID: 83086
[No Abstract] [Full Text] [Related]
4. DTIC and actinomycin D with and without C. parvum immunotherapy in advanced malignant melanoma.
Halpern J; Catane R; Biran S; Fuks Z
Tumori; 1981; 67(3):215-7. PubMed ID: 7281240
[No Abstract] [Full Text] [Related]
5. A trial of imidazole carboxamide and corynebacterium parvum in disseminated melanoma: clinical and immunologic results.
Clunie GJ; Gough IR; Dury M; Furnival CM; Bolton PM
Cancer; 1980 Aug; 46(3):475-9. PubMed ID: 6994866
[TBL] [Abstract][Full Text] [Related]
6. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
Lipton A; Harvey HA; Lawrence B; Gottlieb R; Kukrika M; Dixon R; Graham W; Miller S; Heckard R; Schelzel D; White DS
Cancer; 1983 Jan; 51(1):57-60. PubMed ID: 6821809
[TBL] [Abstract][Full Text] [Related]
7. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Feb; 35(2):171-9. PubMed ID: 312169
[TBL] [Abstract][Full Text] [Related]
8. Treatment of malignant pleural effusions with intrapleural Corynebacterium parvum or tetracycline.
Leahy BC; Honeybourne D; Brear SG; Carroll KB; Thatcher N; Stretton TB
Eur J Respir Dis; 1985 Jan; 66(1):50-4. PubMed ID: 3979476
[TBL] [Abstract][Full Text] [Related]
9. Lung cancer patients treated with Corynebacterium parvum. Phase I toxicity study.
Yadeau R; Bates HA; Fortuny I
Minn Med; 1979 Sep; 62(9):673-5. PubMed ID: 503003
[No Abstract] [Full Text] [Related]
10. Surgical adjuvant therapy of malignant melanoma with corynebacterium parvum.
Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Braun DW; Fortner JG; Oettgen HF
Cancer; 1981 Jul; 48(2):245-51. PubMed ID: 7016302
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant therapy of cutaneous malignant melanoma: a critical review.
Koh HK; Sober AJ; Harmon DC; Lew RA; Carey RW
Med Pediatr Oncol; 1985; 13(5):244-60. PubMed ID: 3897817
[TBL] [Abstract][Full Text] [Related]
12. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly sequential study of melanoma patients. I. Changes in non-specific (NK, K and T cell) lymphocytotoxicity, peripheral blood counts and delayed hypersensitivity reactions.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 May; 36(2):227-36. PubMed ID: 314367
[TBL] [Abstract][Full Text] [Related]
13. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Jan; 35(1):36-44. PubMed ID: 428146
[TBL] [Abstract][Full Text] [Related]
14. Treatment of malignant ascitic and pleural effusion with Corynebacterium parvum.
Webb HE; Oaten SW; Pike CP
Br Med J; 1978 Feb; 1(6109):338-40. PubMed ID: 623981
[TBL] [Abstract][Full Text] [Related]
15. Coparvax for malignant effusion?
Drug Ther Bull; 1983 Oct; 21(20):79-80. PubMed ID: 6641514
[No Abstract] [Full Text] [Related]
16. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
Thatcher N; Mene A; Banerjee SS; Craig P; Gleave N; Orton C
Br J Surg; 1986 Feb; 73(2):111-5. PubMed ID: 3512025
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the effectiveness and adverse effects of a Corynebacterium parvum vaccine made in Czechoslovakia with Coparvax, a British preparation made by Wellcome, in the treatment of malignant pleural effusions].
Marel M; Melínová L; Bednár M
Cas Lek Cesk; 1989 Aug; 128(34):1071-4. PubMed ID: 2790915
[TBL] [Abstract][Full Text] [Related]
18. Immunotherapy of cancer with corynebacterium parvum.
Halpern B
Ann Allergy; 1978 Mar; 40(3):155-7. PubMed ID: 637374
[No Abstract] [Full Text] [Related]
19. Effects of repeated Corynebacterium parvum and BCG therapy on immune parameters: a weekly study of melanoma patients II. Changes in serum immunoglobulins and lymphoid cell subpopulations.
Thatcher N; Swindell R; Crowther D
Clin Exp Immunol; 1979 Jun; 36(3):456-64. PubMed ID: 487647
[TBL] [Abstract][Full Text] [Related]
20. Microscopic changes of the urinary bladder in patients with primary tumors locally treated with Corynebacterium parvum.
Raica M; Ioart I; Gurtavenco A
Morphol Embryol (Bucur); 1989; 35(4):275-7. PubMed ID: 2533966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
